MedTrace Logo

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

NCT03401788 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-13

No results posted yet for this study

Summary

This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.

Conditions

  • VHL - Von Hippel-Lindau Syndrome
  • VHL Gene Mutation
  • VHL Syndrome
  • VHL Gene Inactivation
  • VHL-Associated Renal Cell Carcinoma
  • VHL-Associated Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Belzutifan

120 mg once daily (three 40 mg oral tablets once daily).

Sponsors & Collaborators

  • Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-02
Primary Completion
2027-04-29
Completion
2027-04-29
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03401788 on ClinicalTrials.gov